iRadimed (NASDAQ:IRMD) Releases Q2 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its second quarter 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.440-0.480 for the period, compared to the consensus estimate of 0.460. The company issued revenue guidance of $20.0 million-$21.0 million, compared to the consensus revenue estimate of $21.1 million. iRadimed also updated its FY 2026 guidance to 2.060-2.210 EPS.

iRadimed Trading Up 4.4%

NASDAQ:IRMD opened at $87.15 on Friday. The company has a market cap of $1.11 billion, a PE ratio of 47.62 and a beta of 0.91. iRadimed has a twelve month low of $50.31 and a twelve month high of $107.90. The company’s 50 day moving average is $96.69 and its two-hundred day moving average is $94.02.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating the consensus estimate of $0.46 by $0.03. The business had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, analysts expect that iRadimed will post 1.94 EPS for the current fiscal year.

iRadimed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s payout ratio is currently 45.71%.

Analyst Ratings Changes

Several research firms recently issued reports on IRMD. Roth Mkm reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Lake Street Capital restated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $120.00.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 3,750 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $89.16, for a total value of $334,350.00. Following the completion of the sale, the chief executive officer directly owned 2,198,750 shares in the company, valued at $196,040,550. This represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,750 shares of company stock valued at $4,708,950 in the last ninety days. 36.80% of the stock is owned by corporate insiders.

Trending Headlines about iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

Institutional Investors Weigh In On iRadimed

Hedge funds have recently modified their holdings of the business. Quarry LP acquired a new stake in shares of iRadimed in the third quarter valued at about $40,000. Tower Research Capital LLC TRC raised its position in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the last quarter. Virtus Advisers LLC purchased a new stake in shares of iRadimed in the third quarter valued at about $117,000. Aquatic Capital Management LLC grew its holdings in shares of iRadimed by 210,400.0% in the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $150,000 after purchasing an additional 2,104 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of iRadimed in the third quarter valued at about $164,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.